Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Succession Planning Targeted In Congress As Hamburg Heads For Exit

This article was originally published in The Gray Sheet

Executive Summary

Margaret Hamburg’s departure from commissioner post seems to be proceeding smoothly; proposals in the House 21st Century Cures discussion draft would mandate a similar process always be followed.


Related Content

'Cures' Innovation Fund Targeted At Some Device Provisions In Latest Bill
FDA Commish Hamburg Gets Fond Farewell
FDA’s Acting Chief Scientist Offers Vaccine Continuity As Goodman Departs
FDA Reform Bill Gives Commissioner Fixed Term, Adds Review Board
FDA Reorganization Adds "Directorate" Layer, But Sharpens Agency's Focus
No FDAer For Commissioner, Interim or Otherwise, Rep. Stupak Urges Obama





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts